Sarah Cannon Research Institute-ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2020

  1. Phase Ia study of anti-NAPI2B antibody–drug conjugate lifastuzumab vedotin DNIB0600A in patients with non–small cell lung cancer and platinum-resistant ovarian cancer

    Clinical Cancer Research, Vol. 26, Núm. 2, pp. 364-372

2018

  1. Phase I study of CC-486 alone and in combination with carboplatin or nab-paclitaxel in patients with relapsed or refractory solid tumors

    Clinical Cancer Research, Vol. 24, Núm. 17, pp. 4072-4080

2016

  1. Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer [Supportive Care in Cancer, (2015), DOI:10.1007/s00520-015-2904-5]

    Supportive Care in Cancer

  2. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

    Supportive Care in Cancer, Vol. 24, Núm. 1, pp. 447-455

2013

  1. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial

    The Lancet Oncology, Vol. 14, Núm. 1, pp. 72-80

2009

  1. A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer

    Cancer Chemotherapy and Pharmacology, Vol. 64, Núm. 6, pp. 1139-1148